Skip to main content
Premium Trial:

Request an Annual Quote

Dharmacon, Genospectra to Launch RNA Assays for Gene Silencing Measurement

NEW YORK, July 22 (GenomeWeb News) - Dharmacon of Lafayette, Colo., and Fremont, Calif.-based Genospectra announced today that they will launch a genome-wide line of assays designed to measure RNA changes directly from cell lysates, fresh tissue and archived tissue samples.

 

Genospectra will develop a line of its QuantiGene assays corresponding to Dharmacon's siGenome siRNA reagents targeting human genes. The assays will provide measurement of gene-silencing experiments using small interfering RNA (siRNA). According to the firms, using the QuantiGene bDNA assays with Dharmacon's Smartpool siRNA products will enable researchers to accurately and efficiently validate RNAi gene knockdown studies, as well as compare and standardize data between experiments and laboratories.

 

The partners intend to jointly sell and market the assays to the life sciences research market.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.